Indian regulator in cahoots with industry and has 'skewed' priorities, says parliament
This article was originally published in Scrip
Executive Summary
In what's perhaps one of the most damning reports on industry and the regulatory mechanism in India in recent times, a parliamentary standing committee on health and family welfare has charged that more than 30 new drugs were approved in the country without undergoing clinical trials.